Exhibitors List
French companies at BIO 2009

Ready to distribute your biological reagents in France
Referenced in France as an innovative company, ABCYS distributes and produces biological reagents (antibodies, proteins and kits) for research institutes, hospitals, universities, and the diagnostic , pharmaceutical, cosmetic and animal health research laboratories
Our domain of expertise: Immunology, Cell biology - Cytokines, Elisa assays, Cell culture, Molecular biology
To monitor the sales of its foreign suppliers products lines AbCys is a first class distributor in the field of biotechnology:
A team of high level scientific people and an active sales force at your disposal.
Find AbCys, get results !

ADB PHARMA is a Contract Management Organization specialized in pharmaceutical development. ADB PHARMA is a company of professional managers, immediately operational, who bring their wide experience at a strategic or operational level to Biotechnology or Pharmaceutical companies. ADB PHARMA provides the necessary resources through a Contract Operational Management who is perfectly integrated into your organization for a chosen period of time. ADB PHARMA gives you a privileged access to experts in the following fields: Pharmaceutical and Biopharmaceutical Product Development, Regulatory filing, Quality Assurance implementation. Created in 2004, ADB PHARMA has access to a large source of expertise, from experts on a regular basis to sub-contracting facilities with which contractual agreements were signed to bring operational premises to support development as required by clients.

Advanced Drug Development Services S.A.S (ADDS) is a European Contract Research Organisation (CRO) with offices in France, Czech Republic and in Israel. ADDS offers full coverage of phases I to IV clinical studies for drugs and medical devices, including expertise in biometry and risk management. ADDS is ISO 9001 certified.

Algenics is the blue biotech company focused on novel uses of eukaryotic microalgae as recombinant protein production system. Algenics Biomanufacturing System- Algebiosys™- is based on the use of different microalgae models, selected from existing microalgae biodiversity for their performance as bioproduction systems. Algenics provides its innovative microalgae based solution for biotech and pharmaceutical industries to manufacture therapeutic proteins. Algebiosys™ is effective to produce high-quality proteins on a large scale at a competitive cost.

Founded in 2007, the Alizé Pharma Group is a group of privately held biopharmaceutical companies (based in Lyon, France) and specialized in the development of innovative therapeutics for the treatment of metabolic diseases and cancer. Alizé Pharma SAS is focused on the AZP-01 program, a family of unacylated ghrelin analogs for the treatment of type II diabetes, currently generating proof-of-concept clinical data. Alizé Pharma II SAS is dedicated to the development of a long acting recombinant L-asparaginase, the AZP-02 program, currently at the preclinical stage for the treatment of acute lymphoblastic leukaemia, and to AZP-03, a new program in the field of metabolism.

Alsace BioValley, a key player for the development of biotech companies in France:
- Your entry point to a pool of more than 150 pharmaceutical, biotech and medical technology companies in Alsace.
-Your interface with highly regarded academic research institutes for collaboration and licensing opportunities.
-Your first support for the development of your business in Alsace, ideally located at the heart of Europe. -Your gateway to the tri-national LifeSciences cluster BioValley (France, Germany and Switzerland).

Alsace International is the economic development agency of the Alsace region. We accompany international companies interested in doing business in ALSACE's BIOVALLEY, the leading trinational life sciences cluster in Europe at the crossroads of eastern France, North-West Switzerland and South Baden-Württemberg in Germany.
Alsace's assets:
CENTRE OF EXCELLENCE : In the recent national call for projects, Alsace qualified as the Competitiveness Cluster It is thus recognized as one of the major BioClusters in France
HIGH-QUALITY HIGHER EDUCATION AND RESEARCH ESTABLISHMENTS : More than 15,000 scientists working in over 150 academic and/or public institutions involved in life sciences. HIGH DENSITY OF LIFE SCIENCES COMPANIES,. 40% of the major pharma companies are represented in the BioValley area (Novartis, Roche, Sanofi-Aventis, Lilly, ...). Over 350 companies, 40 000 jobs.
CUSTOMIZED SERVICES FOR INVESTMENT PROJECTS AND FAVORABLE ECONOMIC CONDITIONS: Alsace International provides free and confidential customized services for companies interested in knowing more about doing business in Alsace or in Europe. Services include location information, grant negotiations, access to venture capital, business and scientific contact facilitator, staff integration. AI works in close collaboration with a network of regional partners
AI also relies on a network of branch offices worldwide including in the United States, Canada, Japan, China, Poland etc.

AltraBio delivers comprehensive solutions in exploration, mining and integrative analysis of life science data. AltraBio helps optimize the preclinical and clinical development of candidate compounds. AltraBio interprets the results in the context of current biomedical knowledge and formulates hypotheses for the mechanisms of action underlying the observations.
Application areas:
- Preclinical and clinical development: Quantitative analysis of high throughput experiment data, validation and benchmarking of transgenic and tissue-engineered models, conceptual interpretation of quantitative experimental results, complete range of statistical analysis services relevant to clinical trials etc.
- Technical due diligence and data audit services: Review and validation of database completeness, data quality and internal consistency; verification and validation of the results and conclusions of statistical analysis etc.
- Data management: Biomedical database design and implementation.

ANS Biotech is a preclinical Contract Research Organization (CRO) dedicated to developing disease and efficacy models focused on pain pharmacology.
The company offers a unique combination of an extensive expertise in fundamental pharmacology of pain and a strong background in Research & Development (R&D) for new analgesics.
ANS Biotech supports drug discovery efforts of his clients (customized in vivo studies, especially in the field of inflammatory pain, neuropathic pain and visceral pain) and has access to clinical pharmacology capabilities in pain management.
As an expert partner, ANS Biotech commits to providing pharma and biotech companies with:
Relevant selection of preclinical pharmacology services for successful R&D of innovative analgesics: in vivo experiments & proof of concept studies, mechanism of action studies, therapeutic positioning, consulting
Customized scientific studies (fee for services activities and collaborations) meeting drug discovery and clinical development objectives
Expertise in clinical pharmacology focused on pain and analgesia research (Clinical Investigation Center)
ANS Biotech is a Young Innovative Company and has a French agreement for Research Tax Credit.

APcis is a preclinical CRO. Focussing on predictive animal models, with a total dedication to the 3 Rs policy of reduction refinement and replacement methods the company has developed new models allowing to speed up the development of new drug candidates and to increase the success rate from Phase I to phase III in man.
Infectious diseases: with more than 50 models in rodents, APcis is able to screen and validate targets for new antivirals, antibacterial and antifungal candidates.
Cancer: solid human tumours and homospecific cell lines are followed over time with non invasive ultra high definition and high speed CT scans. Our new methods allow to
Central Nervous System: from 5HT2 KO mice to dog models, APcis has unique insight on sleep and depression analysis.
New imaging techniques, humane models, biochemical pathways and PK-PD techniques in high tech environment.

Ariana™ PHARMA delivers pioneering Data Mining and multi objectives Decision Support solutions for Drug Discovery, Clinical Trials and Safety in order to dramatically accelerate and improve the discovery, development of safe pharmaceutical products.

AtlanBio is a Contract Research Organization focussed on Bioanalytics, certified by the French authorities (AFSSAPS) for GLP compliance.
Chromatography combined to Mass Spectrometry and Immunoassays are the core of the activities.

For pharmaceutical companies looking for high level partners devoted to healthcare and biotech, Atlantic Biotherapies is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France. To ensure the development of biotherapies at an international level, the cluster has developed a broad network of global partnerships, already leading to effective cooperation between cluster members.
Atlantic Biotehrapies gives you access to extended skills, from biodiagnostics to biomedicine. Its stakeholders offer comprehensive and competitive solutions along the entire biotherapeutic value chain, from discovery to patient, with areas of excellence such as biomanufacturing, vector development or clinical evaluation.
THE STAKEHOLDERS : 46 companies - 900 specialist researchers - 14000 healthcare professionals -2 universities - 2 university medical centers - 1 veterinary school - 4 institutes combining fundamental & clinical research
THE BIOTHERAPEUTIC VALUE CHAIN (diagnosis & therapeutic innovations): Basic research - Discovery optimization - Preclinical development - Vector development - Clinical research & evaluation - Biomanufacturing / bioprocessing
AREAS OF EXCELLENCE: Cell & gene therapy - Immunology - Biomaterials - Radiopharmaceuticals.

The Regional Economic Development Agency for Auvergne objective is to structure and promote the region's talents in biotechnologies. One main mission: to canvass successful companies in a position to develop investment projects in Auvergne and to help them set up in the region.

Avogadro is an independent GLP/GMP compliant CRO with 120 scientists and 45, 000 sq ft, based in Toulouse, France and Cambridge, MA, specialising in Pharmaceutical Analysis (method development, validation, and stability studies), CMC & RA, Quality Control (physicochemical characterisation on various products), Bioanalysis (LC/MS/MS assays of pre-clinical and clinical studies), ADME (including metabolite profiling and identification), Pharmacokinetics (Bioavailibilty, Bioequivalence), including in life phases in laboratories species and Environmental Impact Assessment.

Established in 1989, BBV offers confidential R&D services, mainly to plant breeding and agrochemical companies : tissue culture (haplomethods, embryo rescue, micropropagation...) ; screening for disease resistances ; marker assisted breeding ; phytopharmaceutical products evaluation ; sensory analysis.
(more than 50 field crops and specialty crops are investigated).

We are a leading predictive integrative biology company that helps its clients and partners to significantly boost the outputs of their R&D programs using our proprietary modeling approach.
As a research-based biotech company we creates CADI™ models to generate businesses with immediate applications through contract or collaborative research programs.

CADI™: The 'first-in-class' answer to explain the non-linear mechanisms of diseases and thus, reveal pertinent biomarkers & therapeutic targets.
-2003, CADI™ models 'first-in-class'. Publication with INSERM unit 553 of the world's first successful independently validated model of a complex human disease in Nucleic Acids Research.
-Mechanisms of life being integrative non-linear processes, they require 'specific' approaches to be correctly understood: CADI™ models, belong to the non-mathematical class of models.
-CADI™ models building approach, based on the disruptive 'negative selection' concept, and an innovative synergic collaboration between experimental biology and integrative biology has proven to allow researchers to take the best possible decisions for the best possible results in a minimum of time and resources.

BMSystems' operational proofs :
- 7 models produced in 5 major medical areas, 2 publications in 'cancer' with INSERM, 1 patent in 'Psychiatric disorders' and 1 scientific publication pending in 'Neurodegenerative diseases' with CEA** Life Sciences, 2 patents in infectious diseases, 1 operational spin-off in Biodefense and Biosecurity, 2 technology platforms, 2 bacterial strains under development.

CADI™: The validated operational answer to address key R&D challenges.
- Disease understanding/ redefinition,
- New therapeutic strategies, new associations of existing molecules,
- Identification/selection of pertinent predictive Biomarkers,
- Predictive efficacy and safety profiles, drug (re)positioning /(re)profiling/ rescue,
- R&D programs evaluation,
- Proposition of new bioproduction processes through micro-organisms' modifications, etc..

*CADI (Computer Assisted Deductive Integration) **(only from our non-confidential programs)

BIOalternatives is a contract research organization providing in vitro assays and services for drug discovering and clinical samples analysis.
Primocultures, ex vivo models, high content screening, proteomic and transcriptomic tools are a part of the informative solutions provided and managed by our team.
Our research is focused on: Neurodegenerative disorders, neuro-inflammation and neurophysiology ; Wound healing, skin inflammatory diseases (psoriasis...) and dermatology ; Inflammation and immunomodulation.

Biocitech is a technology park for life sciences, located on the outskirts of Paris which offers a world-class environment and services for the development of biotechnology, biopharmaceutical and fine chemical companies.

BioSquare 2010 comes with a new format!!
BioSquare is one of the premier European Life Science partnering event.
Every year, BioSquare brings together decision-makers from leading biotechnology, pharmaceutical and investment companies from around the world for 2 to 3 days of focused networking, presentations, expert panels and one-to-one partnering meetings
BioSquare in 2010 will be held in Switzerland and will have an entirely revamped format!
A new partnering software, the most user-friendly in the industry, letting you plan and organize your agenda as you wish; more social events & networking opportunities, high level panels and workshops with priority to business and technology and an international exhibition.
Join leading pharmaceutical, biotechnology and investment companies in Switzerland and maximize your partnering potential!
Come to experience the new BioSquare 2010 in Switzerland!
BioEvents SAS is the organizer of BioVision, the World Life Sciences Forum and of BioSquare
www.biosquare.com
www.biovision.org

Clinical Research and Regulatory Affairs in Early Development in Oncology and Biotechnology
Your early development in Europe

Bionest Partners provides management consulting and financial advisory services tailored to the healthcare and life sciences industries. Bionest has in-depth expertise in consulting activities including strategy, due diligence, operations and market entry, and corporate finance activities including M&A, valuation, equity research and IPO support. Based in Paris and New York, the company has a broad client base, including biotechs, large pharma and investment funds in the US and Europe.

BioQuanta is a biotechnology company dedicated to realizing the potential of your therapeutic compounds. Its unique 'In silico' and metabolic exploration platforms generate highly accurate and reliable results at unmatched costs and deadlines to enhance the value of your leads.

Biotrial is an independent European CRO, offering a full range of services to the biotech and pharma industries: phase I studies in healthy volunteers & specific populations, phase II-IV trial management, data management, biostatistics, ECG and imaging central lab, medical writing & non clinical pharmacology. With over 80 phase I studies/year, 150 beds in 3 different phase I units, Biotrial, leading service provider in early development in Europe, has a specific approach for biotech & start up companies, and performs global studies from Non Clinical to Phase IV. Areas of expertise include first administration in man and clinical pharmacology, in the fields of CNS, CV, immunology, inflammation, infectious diseases, hematology, endocrinology, metabolism and ophtalmology. Biotrial has also established a strong specific group for oncology services with links to anticancer institutes and oncology departments throughout Europe, performing trial from early development up to phase III.

Bretagne International is a non-profit association commissioned by the Regional Government of Bretagne (Western part of France) to:
o assist Breton companies in their international development.
o identify projects of investment in Bretagne and support foreign investors.
Relying on our excellent knowledge of companies ' know-how and economic structure in our region, we can assist YOU with free and confidential assistance through the different stages of your project to create or acquire a company in Bretagne: data collection, identification of and introduction to potential partners, proposals of locations, assistance before, during and after the installation...

C.RIS Pharma is a Contract Research Organization (CRO) specialized in the preclinical development of new active molecules in the fields of Cancer, Metabolic, Neurodegenerative and Genetic diseases and acts as a partner for Cosmetic, Agrofood and Veterinary companies.
C.RIS Pharma offers an extensive range of services throughout the drug development process with in vitro and in vivo studies performed according to GLP: Stability studies, Process validation, Regulatory Affairs, Biosafety, ADME and Immunogenicity...
C.RIS Pharma also possesses various models for in vitro and in vivo screening and pharmacology assays for the evaluation of molecules in antitumor activities (xenografted, orthotopic or syngenic animal models), chemotherapy, diabete, inflammation, allergy, dermatology and neuronal diseases.
Other services such as biochemistry and hematology analysis, genotyping, detection of animal pathology and genetic footprint are proposed for our sponsors.
With a great expertise, C.RIS Pharma supports biotechnology and pharmaceutical companies pre-clinical program by proposing tests adapted to their specific needs.

Germain & Maureau is an Intellectual Property law firm and has a team of highly qualified attorneys (many of them having PhD) providing advices to clients in the pharma and life science sector. Our firm works with clients ranging from start-ups, universities to multinationals and provides the full spectrum of patent services from patent drafting and prosecution to licensing and due diligence.

The principal mission of the Cancer-Bio-Santé cluster is to improve management of the continuum of cancer care by adopting a unique and broad approach throughout the fields of prevention, diagnostic, treatment and patient monitoring, by synergizing all the resources of the Midi Pyrenees region necessary to treat cancer: education, public and private research, clinical research and industry. Cancer-Bio-Santé will contribute to the development of the The Toulouse Campus Cancer, a 220 ha Biopark, which will be dedicated to the fight against cancer, combining and integrating both institutions and industry resources. The Cancer-Bio-Santé cluster is supporting in the Midi Pyrénées and Limousin regions more than 2,000 people involved in R&D in public sector and 1,650 in private sector. Overall 230 companies in the sector of health (9,000 jobs), 63 biotechnology companies, 2 international pharmaceutical companies (8,000 jobs), 30 companies involved in health food as well as 2,100 companies involved in information technologies (14,000 jobs) are contributing to the dynamic of the cluster.

Cancer Campus will be the Paris biocluster dedicated to cancer innovation. On a site housing one of the largest European cancer center (Institut G. Roussy), local authorities, academic and industrial partners are setting up the project.

CBB Développement, a centre for technology transfer acts in the area of biotechnology and fine chemistry. CBB offers companies its skills in the development of innovative projects in the fields of fine chemistry, cosmetics, pharmaceuticals, food, agriculture and environment. CBB is also your access to the Western France partners' network (companies, incubators or scientific parks).and Food regional biocluster (Valorial) or seaproducts regional biocluster (PMB).

Cellectis is the world leader in meganuclease based genome editing. Our industrialized production platform allows to engineer highly specific (22bp recognition site) and effective custom nucleases that induce double stranded DNA breaks while promoting local homologous recombination and non-homologous end joining that can be used for gain or loss of function modifications. Cellectis is seeking collaborations and partnerships to exploit its technology in the field of human therapeutics, agriculture and bio-manufacturing.

Cerep's mission is to provide pharmaceutical companies with high-quality services in drug discovery and drug development. Cerep provides solutions allowing faster and cost-effective drug discovery by identifying at early stages the most promising drug candidates as well as eliminating those compounds likely to fail in development.
Cerep offers preclinical drug discovery services for in vitro pharmacology, in vitro ADME-Tox & in vivo PharmacoKinetic.
Cerep has developed unique know-how based on technologies of in vitro screening and of profiling using its proprietary database BioPrint®, which allows the modeling of clinical effects of drug candidates from their molecular properties.
Cerep's technologies benefit to more than 460 pharmaceutical and biotechnological companies worldwide including most of the top pharmaceutical firms.
Cerep's next objective is to open satellite laboratories, closer to where compounds are synthesized and drug candidates optimized, thus further decreasing turnaround time for discovery teams to obtain data.

CEVA (Centre d'Etude et de Valorisation des Algues) is a private Contract Research Organization (created in 1982, 25 people, turnover 2.3 M€, ww. footprint).
Our mission is Business development using Algae.
We offer Knowledge Intensive Business Service on Algae, including industrial pilot facilities, for a wide range of applications addressing tremendous markets sizes with significant growth rates (i.e.: health, food/feed supplements, cosmetic, green chemistry, energy, ...).
Sourced by a network of worldwide leaders in Algae fundamental research and supported by private customers eager to launch disruptive products, CEVA provides a unique single entry point to the Algae Application Business.
Our service integrates the entire workflow from disruptive ideas, Algae raw material management, Algae processing, biotechnology, product formulation, industrial scale up and technology transfer to the customer's company.
'Bring your issues, if Algae is the solution, we'll do the rest.'

CIT is an independent and private owned CRO specialized in safety and health research. In more than four decades CIT has conducted projects for pharmaceutical, veterinary pharmaceutical, biotechnological, chemical, agrochemical and consumer product companies and have contributed to many registrations around the world.
Studies are performed to meet national and international guidelines, Good Laboratory Practice regulations (GLP) and with strict respect of ethical standards (CIT and AAALAC accredited).
CIT is certified by the regulatory authorities/agencies from Europe/ France - AFSSAPS & AFSSA, the USA - FDA & EPA and Japan - MHLW & MAFF.
QUALITY : Scientific advice on your project and interpretation of your data
FLEXIBILITY : Full package study, specific or multi site studies upon request
SCIENCE DRIVEN : Biomarkers and Genomics high tech platform

Clean Cells is a Contract Service Organisation providing biosafety testing, development and manufacturing services for biotechnology and pharmaceutical companies world-wide. Our GLP in vitro / in vivo assays support the development of healthcare products from R&D stage trough to clinical trials and licensed products (recombinant proteins, monoclonal antibodies, vaccines, cell and gene therapy products) in compliance with regulatory requirements (FDA, EP., ICH,..).
1. Clean Cells has steadily expanded the range of services since it's founding in 2000, which can be subdivided in : Biosafety testing (raw material testing, characterisation of Master and Working Cell Banks, intermediate and final product testing) - This involve assays such as mycoplasma, sterility, virus detection, genetic stability, kariology, isoenzymes, DNA fingerprinting, residual DNA and HCP, endotoxin, general safety...
2. Production and Cell storage (cell and virus banking, manufacturing process development) at a research grade and GMP standard at the end of 2009;
3. Process validation : Viral and mycoplasma clearance, media fertility testing;
4. Customized cell based assays for R&D and lot release purpose (biopotency assay, cytotoxicity assay (ADCC), clone selection, primary cells immortalization, viral vector productions...).

CLINSIGHT is a company specialized in the edition of clinical trials management. Our solution, CAPTURE SYSTEM, is a comprehensive software allowing you to carry out data management, monitoring and on-line trials efficiently.

The CRITT Sante Bretagne is an innovation and technology transfer centre that works for research units and companies involved in the R&D of health-care applications in Brittany, Western France (70 public research units and 150 companies). Its missions are to support and develop partnerships, to provide technological assistance, to assist project leaders, to promote and support development of SMEs, to provide scientific, technology and regulatory surveys.
The CRITT Santé Bretagne's fields of expertise include:
- Medical devices and biomaterials
- Medical imaging and new information and communications technologies
(NICT) for the health sector
- Drug development and new therapies
- Nutrition for human health
- Biotechnologies and genomics.

DBV Technologies (DBV) is a biopharmaceutical company engaged in the development of non­invasive epicutaneous delivery technology, products, and specializing in allergy. The Company's core technology, VIASKIN® is a unique epicutaneous delivery system designed for the delivery of allergens into the outermost layer (epidermis) of the skin. This technology is patented worldwide. One of the first applications of VIASKIN® is in the diagnosis of allergy and the epicutaneous immunotherapy (allergy treatment). DIALLERTEST® Milk is the first product put on the market and designed specifically for the diagnosis of cow's milk protein allergy which occurs very frequently in infants. DIALLERTEST® Milk is sold in more than 20 countries worldwide since 2004. Epicutaneous immunotherapy (desensitisation) : clinical proof of principle (Ph II) has been achieved in cow's milk protein allergy desensitisation studies, enabling rapid start of clinical trials in peanut allergy desensitisation studies. First in man clinical trial in the US in Q4-2009. Cosmetology: the use of VIASKIN® a proof of principle in anti-wrinkle treatment is being investigated. On 22/01/2009, DBV announced it successfully closed a €6million (EUR) investment with new investor ALK-Abello, a leading worldwide immunotherapy company as minority shareholder, and returning investor Sofinnova Partners. DBV will use the €6million (EUR) investment to progress Phase I clinical trials for its peanut allergy treatment.

Diverchim is a chemistry-based CRO assisting its customers in accelerating their Drug Discovery & Process Development. Diverchim is committed to carrying out the customer's confidential contract research on a fee for service basis.

Domain Therapeutics (formerly Faust Pharmaceuticals) is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets.
Domain Therapeutics is using its innovative and proprietary technology platform DTect-All™ to identify orthosteric and allosteric ligands of GPCRS, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-All™ is able to address difficult GPCRs such as orphan and peptidic GPCRs.
The company's pipeline is composed of new chemical entities originally identified using our proprietary technology ranging from hits to preclinical candidates targeting hot GPCRs for leading indications such as schizophrenia, Parkinson's disease and diabetes.
Domain's objective is to partner its R&D programs at the preclinical candidate stage. Two programs are available for partnership, an A2A-antagonist program for Parkinson's disease and an A3-antagonist program for Glaucoma.
Other programs aiming at identifying PAMs for challenging targets such as mGluR4, mGluR2 or GLP-1R are at an earlier stage of development. Domain is open to collaboration with Biotech or Pharma partners to jointly continue their development.

Speed-up discovery studies & select highly drugable candidates with DRUGABILIS, the first CRO specialized in pharmaceutical drugability : formulation for biologists, salts & polymorphism, preformulation...

Elan Software Systems is a leading provider of Manufacturing Execution System (MES) dedicated to Life Sciences. The XFP suite provides advanced modules for warehousing, weigh and dispense, work instructions and electronic batch record.

ERYtech Pharma is a specialty pharma company developing new generation medicinal products through encapsulation of drugs into red blood cells.

The Essonne Chamber of Commerce and Industry is a public institution whose role is:
- to represent the general interests of industry and commerce in its district localy and internationaly
- represent the companies to the county administrative authorities
- promote the companies and local development

Located in southeast France in the Provence-Alpes-Côte-d'Azur and Languedoc-Roussillon regions, EUROBIOMED is gathering the Health players along the French Mediterranean border.
With a network of over 400 companies, which are mainly small and medium-sized innovative firms, 8 universities, a range of higher education establishments that train some 39,000 students, 400 research laboratories, 4 university teaching hospitals and an inter-regional headquarters for clinical research, EUROBIOMED is on the way to become one of the clusters leaders in Europe.
The objectives of this cluster are to develop the health business in the south of France through innovative projects in partnership, to facilitate the establishment of young innovative companies, to help small companies in their implementation and development, to stimulate the economic development by accessing and penetrating new job-creating markets and to initiate international cooperation and inter-sectorial projects
The association's ultimate objective is to become a 'one-stop shop' for offering assistance to all the stakeholders, facilitating access to information from sector experts and providing project support.
EUROBIOMED is also accredited by the French government as a competitiveness cluster that federates all the key stakeholders in life sciences and technologies in order to develop new drugs and services for the diagnosis and treatment of emerging pathologies and orphan diseases.

EUROFINS-OPTIMED Clinical Research is a Contract Research Organization (CRO), which offers its experience in Early Drug development (Phase I-Phase II studies)
Located in Grenoble and Lyon, France, we has led several hundreds of clinical studies on behalf of the pharmaceutical and biotechnology companies, with the aid of : A 60-bed Clinical Pharmacology Unit for Phase I studies in Grenoble - A 14-bed hospital based ClinPharm Unit in Lyon - An experienced and stable clinical staff of physicians, study nurses, technicians and scientists. Data Management, Statistics, monitoring and Medical Writing services
We perform many types of studies in early development : Entry Into Man , Bioavailability, Bioequivalence, Interactions, PK/PD, Qt/Qtc, Metabolism, Food / Gender /Age effect... - Section and up-to-date equipment : ECG, Telemetry, Holter ECG, BP, SpO2 Monitoring, Platelet Aggregation, EEG, Psychometric Tests, Respiratory Tests, Polysomnography ... - Our recruitment department now has a file of over 12,000 rigorously selected volunteers. We have also developed more specific populations: diabetics, dyslipidemic subjects, obese persons, subjects with high blood pressure, etc.
The site of Grenoble is certified ISO 9001 : 2000 for all the activities: set-up, conduct, follow-up of clinical trials, and data analysis. This certification underlines the international activity of Optimed

FOGALE Biotech is known worldwide for supplying the biopharmaceutical companies with its Biomass System, an on-line capacitance Biomass sensor that is monitoring viable cell density in bioreactors from lab to cGMP production plants.The Biomass system is routinely used for monitoring animal cells in suspension or anchorage dependent processes but also to monitor yeast or bacterial fermentation in batch and fed-batch processes with high biomass concentration. FOGALE now brings its technology into the disposable applications with the single use version of the capacitance sensor: the Biodis Series. Additionally the company launches the BIOPOD Series: multiple high density and versatile fermentation - cell culture devices at mini scale. Scale up solutions for all kind of processes: the f800 version is a multi parallel multi-fermentor at 80 ml scale ; the c8000 version is a multi parallel multi-bioreactor at 800ml scale with semi or fully disposable bioreactor solutions for suspension or adherent processes The Biopod Series is proposed with full and advanced control of Temperature, pH, Oxygen, level and biomass plus various automated loop as e.g. automatic induction based on biomass control.

FORENAP PHARMA is an International 'One-Stop-Shop' CRO specialised in early Drug Development and Research in Neurosciences. Our structure and network enable us to carry out a 'full service package' and offer consultancy services from Drug Discovery to Marketing Authorisation. Phase I studies in all therapeutic areas are performed in our 72 highly monitored bed equipped centre. Moreover, FORENAP owns a unique technological platform (wake and sleep-EEG (36 beds), 'At your site EEG', MEG, MR, PET scan, Holter ECG...) combined with in-house expertise for investigating Central Nervous System active compounds. In addition FORENAP carries out phase II & III studies mainly in patient suffering from psychiatric and neurodegenerative disorders.

Listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111), Genfit is an innovative biopharmaceutical company, headquartered in Lille, France with a US subsidiary in Cambridge, Massachusetts. Genfit is taking a multi-pronged approach in developing treatments to address unmet medical needs in Cardiometabolic and CNS disorders, such as, type II diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer's. By focusing on early diagnosis, preventive solutions and therapeutic treatments, Genfit seeks to improve the quality of patient's lives. This approach is generating a strong portfolio of therapeutic products, tools, and clinical biomarkers. Genfit's efforts have also yielded a strong and broad intellectual property portfolio.
Genfit, as a self-financed organization, has a balanced business model of, proprietary internal programs as well as, a strong track record of partner supported programs and collaborations. This strategy allows the company to manage the risks associated with the programs, and at the same time, build value for its shareholders. Genfit, on its own and in collaboration with its pharmaceutical partners, has created a rich and diversified pipeline of drug candidates in various stages of discovery and development. The Company's world-renowned scientific expertise, notably in Nuclear Receptors, has turned Genfit into a European biotechnology leader.

GENOPOLE is France's leading biopark dedicated to biotech & genetics research. It brings together private and academic labs, biotech companies and higher education facilities (University of Evry Val d'Essonne) on a 90,000 sqm site. With 23 research labs and a portfolio of over 60 biotech firms, therapeutic innovation is a key concern for Genopole stakeholders. Genopole's objective is to reinforce technology transfer to the industrial sector; create and mature biotech companies.

GenOptics is a laboratory instrumentation company focused on the development of high performance systems with advanced optical imaging (SPRi) to quantify and monitor biomolecular interactions. GenOptics systems have direct applications in the demanding fields of proteomics, drug screening and drug discovery.

Development of tailor-made transgenic rat and mouse models for target validation and drug development through innovative technologies (humanization, RNAi, inducible system) improving the security and relevancy of in vivo programs.

The 'Grand Toulouse' urban community brings together 25 towns and 660 000 inhabitants. Toulouse is the 4th largest city in France and one of the most attractive city in Europe. The 'Grand Toulouse' is hosting 3 competitiveness clusters, Aerospace Valley, Cancer Bio Heath, Agrimip Innovation and develops majors projects. Toulouse is one of the leading regions in Europe for research and development - 500 laboratories, 20000 employees in research, 114 000 students - with an ambitious project, The Toulouse Cancéropôle, a campus dedicated to the fight against cancer, combining the strength of innovative public and private sector.

Adebag, Grenoble Bio Network: a catalyst for the Grenoble Biocluster
- Federating the professional community, at a regional and European level
- Accompanying entrepreneurs to fast-track start-up development
- Managing innovation through cooperation
- Enhancing the international image and visibility of companies
Adebag: today represents: 2 universities; 1 teaching hospital; 2 research centres;27 companies and start-ups; 3 major diagnostics companies: BD, Roche Diagnostics and bioMerieux.
Grenoble, centre of excellence in diagnosis and personalised medecine in 3 key therapeutic directions: Infectiology, Neuroscience and Cancerology, with recognised skills in 4 major technologies: imaging, biomarkers, biochips and pharmacogenomics.
- Two projects with a broad scope: ADNA and Nanobio
- 3 major diagnostics companies: BD, bioMerieux and Roche Diagnostics

With a population of 400 000, Grenoble-Alpes Metropole concentrates key research actors, specially in the health/biotech sectors. Biotechs are one of the strong axis of its economic development policy

Howrey is an international law firm consisting of three premier practices: Antitrust, Intellectual Property and complex Commercial Litigation and Arbitration. This focus has assembled, in one firm, effective, efficient and comprehensive advocacy capability and resources available anywhere. Howrey brings together experienced practitioners who are highly recognized for their patent, competition and regulatory work in the life sciences sector, including bioscience, biotechnology and pharmaceuticals. Having specialists in this field in each of its 10 offices in the United States and its 6 European offices of Paris, Brussels, Amsterdam, London, Munich and Madrid allows the firm to offer its clients, wherever and whenever the need arises, a transnational, national or local approach to their IP matters. Howrey has constantly ranked among the best and received many distinctions. In 2008, the firm was named Global Patent Law Firm of the year, for the fourth year in a row, and received the Top U.S. Firm in Europe award for its IP practice. In France, Howrey's IP team is recognized for its particular expertise in the life sciences as well as other high-tech sectors, including optical storage, data compression and heavy industry.

HTL s.a.s. was created in 1992 and is specialized in the manufacture, purification and research and development of Sodium Hyaluronate (HA). It's production is by biosynthesis using a natural, non OGM, bacterial strain (Mw from 1000 Dalton to 4 million Dalton. HTL's production facility is cGMP, holds Certificates of Suitability with the European Pharmacopoeia for low and high Mw Sodium Hyaluronate, is ISO 9001 (2000) and has a Master File (MAF) filed with the FDA (US),the TGA (Australia) and the Ministry of Health in South Korea.

IATEC Clinical Trial Services is an independent, full-service Contract Research Organization (CRO) that offers a comprehensive package of research services for the pharmaceutical and medical devices industry. Working closely with our clients, we are committed to providing customized services that meet the required standards of quality - on time and within budget.

ImmunID offers innovative immunomonitoring solutions and Biomarkers to measure the impact of immunotherapy on the immune repertoire for a personalized medicine.

In-Cell-Art is a biotech company that has developed and implemented innovative formulation technologies (nanospheres, nanocapsules, lipids) for the pharmaceutical development of macromolecular drugs (DNA, siRNA, proteins)

Our mission is to bring entrepreneurs and researchers together :
- Pro-active detection of innovative projects (individual, academic, entrepreneurs, SMEs)
- Strategic guidance during incubation: risk analysis, business planning support, mentoring, access to premises and to financing
- Training of innovative entrepreneurs

Iris Pharma is a world-class service provider for drug and device development in ophthalmology. We provide strategic consulting, bioanalysis, pre-formulation, preclinical studies, Phase I-IV clinical trials in Europe and North America.

Kayentis is the leading provider of Digital Pen & Paper solutions for the clinical trial industry. Kayentis provides software solutions to life science companies (Labs, CROs, biotech, Pharma companies) which optimize data collection and processing, thanks to its Digital Pen and « Smart » Paper. Kayentis provides its solutions for industries which are subjected to high constraints of data sharing and security. Kayentis proposes solutions which cover companies' needs at each stage of their drug life cycle development: from R&D, Pre-Clinical, Clinical, to Post-Market and Sales. To date, Kayentis has conducted 50 clinical trials in over 50 countries / 37 languages using its Clin'Form® solution. Clin'Form® provides a single, integrated platform allowing companies to collect CRF, patient diary and monitoring report data, significantly streamlining clinical trial costs. Kayentis is located in Philadelphia, PA - USA and Paris, France.

LFB, 1500 employees, is a French biopharmaceutical company specialized in therapeutic proteins. With a 2008 turnover of €353 million, the company is essentially structured around two specialized subsidiaries. LFB Biomédicaments produces and sells a wide range of plasma-derived medicinal products. At present (2009), it is France's third largest hospital drug specialist, with activities in immunology, hemostasis and intensive care. Its 19 products are administered to over 500,000 patients each year and target 80 serious and sometimes rare pathologies. LFB Biotechnologies focuses on the group's R&D and biotech activities in two core areas: monoclonal antibodies and recombinant proteins through transgenic animal technology. R & D budget is €86 million in 2009. Between 2004 and 2007, LFB created 4 subsidiaries, 3 in Europe (UK, Germany and Belgium) and 1 in Brazil.

Eurasanté, the agency dedicated to healthcare & biotech activities in Northern France, promotes the Lille cluster and bio-business park where 100 healthcare & biotech companies are settled within the largest European university hospital complex. We assist firms in setting-up in Northern France. Eurasanté hosts EuroBiO 2009, 23-25 September 2009 in Lille, France.

Lyon BioAdvisor is a free customised service in life sciences. Our mission is to support your company with its development in the Lyon area. We provide links to companies and research centers from Europe most important bio-clusters in immunology, vaccinology, diagnostics and immunotherapeutics, and to industry-leading companies in cancer research and nanotechnology.

The Lyon Chamber of Commerce and Industry is a public organisation. Its mission is to:
- lobby the public authorities in the interest of companies and retailers in its district
- promote Lyon's advantages, attract inward investment and newcomer businesses
- assist companies, retailers and service businesses in every stage of their development
- build and manage facilities needed for local economic development.
The Lyon CCI's international department provides local French companies with international development consulting by giving economic, strategic, tax and legal advice for integrating foreign markets.

Lyonbiopôle is a world competitive cluster focusing on human and animal infectious diseases. It draws strength from the vitality of the Lyon/Grenoble area and efficient synergies in industrial biology, structural biology and micro/nanotechnologies. Designed as a 'factory' for multi-partner R&D projects, Lyonbiopôle acts as the interface for bringing together big companies and public research. The ambition is to boost innovation supporting the competitiveness of firms and the local region.

The Medicen Paris Region cluster unites all key life science and healthcare players in the Paris metropolitan area. The cluster brings together the highest concentration of healthcare expertise and resources in Europe and focuses on advanced technologies for healthcare, innovative drugs and new molecular, cell and gene therapies. It also leverages the assets to be found in of the world's leading metropolises including financial infrastructure, real estate and transportation networks. Our top priority is to bring up the region's competitiveness and international attractiveness, in terms of high-level therapeutic innovations, to best-in-class level. We seek to create high added-value jobs in life sciences.

Metabolys provides early during the research and development phase a panoramic view of the pharmaco-toxicological interactions of small amounts of drug candidates with metabolic pathways using a cellular metabolomic approach in vitro.

Mutabilis is a biopharmaceutical company which specializes in the discovery and development of antibacterial drugs. The company discovers and develops innovative, first-in-class anti-infective therapies which address current antibiotic resistance issues and target severe bacterial infections. The priority target for Mutabilis' novel therapeutics is the nosocomial (hospital-acquired) infections market. With its in-house chemistry and biology departments, Mutabilis has the capability to identify new antibacterial therapies in the fields of vaccines, antibodies and classic antibiotics. Mutabilis aims to discover novel antibacterial therapies with a new mechanism of action and develop them up to the clinical proof-of-concept phase (Phase I-IIa). Once clinical proof of concept has been achieved, Mutabilis will out-license its products.

Neurokin develops a new generation of neuroprotectants, NK drugs, which are proprietary selective kinase inhibitors and more specifically cyclin dependent kinase inhibitors (CDK inhibitors) to treat and prevent acute neurological diseases such as stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury (TBI). Our objective is to bring our first drug candidate into the clinic in less than 18 months. Proof of concept with a compatible human administration route has been shown in different in vivo models including stroke (permanent and transient), epilepsy and traumatic brain injury pre and post-treatment. In the tMCAO model in rat, NK-102 is able to decrease the total volume of infarction of 30% and the volume of cortical infarction of 50% at least 2 hours after the beginning of ischemia.Neurokin will develop drug candidates up to clinical phase 2 and license them to the pharmaceutical industry or, according to the opportunities, will co-develop NK-102 for some clinical indications.Neurokin will perform its development programs either through VC financing or through a partnership with a Pharmaceutical company interested in bringing them further into the clinic.

NicOx is a biopharmaceutical company applying its proprietary nitric oxide-donating technology to develop New Chemical Entities for unmet medical needs, in the therapeutic areas of inflammatory and cardio-metabolic disease.

NovAliX is a private company combining structural biology, medicinal chemistry and an in-house developed screening technology to conduct integrated drug discovery programs. NovAliX provides target-driven solutions for drug discovery offering access to diverse and relevant approaches such as natural product-based drug discovery and fragment-based drug design (FBDD). The fragment selection process (FAMASS) is powered by an innovative mass spectrometry screening technology delivering high-content information on compound-protein interactions (binding evidence, stoichiometry, reversibility, specificity, binding affinity...). This biophysical method is also advantageously used for library hit validation and hit or lead analog ranking. In addition, through its integrated platform in chemistry and biology, NovAliX provides various single services in organic synthesis and protein crystallography. As of today, NovAliX operates in Strasbourg with 60 scientists in state-of-the-art facilities (1600 m2) equipped to carry out multidisciplinary research.

Lyon and its region are today one of Europe's most dynamic and attractive regions in the field of Life Sciences.
Key Figures
- A strong industrial base : 600 companies (including 60 « pure biotech » firms), encompassing more than 100 000 employees in the Life Sciences sector.
- A favorable clinical environment : 40 hospitals (one of the largest university hospital concentrations in Europe : 22,000 beds in public and private establishments), accounting for 36 000 employees.
- Cutting-edge research and educational programs: 9 000 jobs, 150 public laboratories, 20 000 students in Life Sciences and Healthcare, 150 incoming PhD students / year, 55 million € in technology transfer / year.
- Renowned industrial and scientific excellence, focusing on three major areas, infectious diseases, oncology and neurosciences with organized networks :
Lyonbiopôle, world-class cluster focusing on the fight against infectious diseases and upstream of it, FINOVI, a specialized advanced research network in infectious diseases, creating the right conditions for attracting international research teams at very high standard
The Lyon Auvergne Rhône-Alpes Canceropôle, CLARA, France's second-largest cancer research hub
3 specialized research and treatment networks, to enhance applied clinical research in the fields of neurosciences, cancer and transplantation.

French CRO focused on bioavailability of compounds issued from life sciences. OROXCELL has an extensive expertise in both innovative formulations to improve oral absorption, and new in vitro technologies to evaluate ADME parameters, pharmacokinetics and biopharmaceutical discovery.
ADME: Caco-2, P-gp interaction, metabolic stability (S9, microsomes, hepatocytes), Cyp inhibition, induction, pKa in rodents, tissue distribution - Physico-chemistry: Log P, Log D, pKa, stability testing
Bioanalysis: LCMS, LCMSMS, LCUV, radioactivity.

The Paris Region Economic Development Agency (PREDA) provides a range of business development services to ensure the success of your business setup in Paris Region - take advantage of the Agency's free, confidential services tailored to your needs. We can put together a personalized support package to guide you through each stage: location, administrative procedures, technological and commercial opportunities, recruitment.
The Agency monitors your development long after you set up in Paris Region and does everything it can to build a thriving business ecosystem to support your business.PREDA has 3 key aims:
- Help create and safeguard jobs in Paris Region
- Enhance Paris Region's economic attractiveness
- Support areas in the region affected by economic changes

Brief Company Description: PhenoPro is a leading provider of comprehensive mouse model phenotyping services of high scientific quality to support biopharmaceutical basic and translational research.
Additional Company Information: PhenoPro is a spinout of the Mouse Clinical Institute (Illkirch, France) and an entry point to a contract research integrated network (CRNET)

Polyplus-transfection is a research-focused biotechnology company developing and marketing innovative solutions for transfection and therapies based on nucleic acid delivery. Polyplus provides outstanding quality reagents for standard DNA transfection up to human gene therapy, as well as for protein production and siRNA delivery. Besides its transfection expertise, Polyplus-transfection is developing a new kind of modified oligonucleotides, named ZNA™, which show a greater affinity for nucleic acids. These versatile modified oligonucleotides are new precious tools for all nucleic-acid detection methods and for molecular diagnostic applications.

As a niche CRO, we specialize in animal pharmacology, concentrating on our recognized excellence in selected domains of competence.
With over 25 years of experience, the company has developed a wide range of test procedures and models in laboratory animals covering most of the pharmacological studies for evaluating the Efficacy and Safety of human and veterinary drug candidates. The range of our activities covers most of the therapeutic areas of the central nervous system, including pain, cardiovascular, respiratory, gastro-intestinal, and renal/urogenital systems. More recent developments are in the domain of metabolism & eating disorders.
We perform regulatory studies (ICHS7) in full compliance with GLP.
Our Research facilities in the Mayenne region cover an area of 2 500 sqm. The construction of a new Research Center of about 6 000 sqm started in 2008. We have 250 sqm offices near Paris.
We have an international coverage and we currently work with more than 100 different companies from North America, Europe, Israel, India, Australasia... (big pharma, small/medium pharma, start-up/biotech companies). Our Research has been used to select and advance numerous drug candidates towards clinical development and registration.

Prestwick Chemical Inc., a premium provider of medicinal chemistry services was founded in 1999 by Prof. C. G. Wermuth, a world-known expert in medicinal chemistry, along with top scientists from Strasbourg University. Prestwick Chemical offers a broad range of expertise in all areas of medicinal chemistry, ranging from custom synthesis including patent exemplification, to research projects aimed at hit validation, ligand profiling, and lead optimization. Prestwick's experienced team of intuitive medicinal chemists develops innovative synthetic strategies tailored to the client's needs. They are supported by state of the art computer-aided molecular design, large-scale virtual screening and expertise to address ADME/TOX and selectivity issues. In addition to research services, Prestwick Chemical provides the pharmaceutical industry and academic research laboratories with a supply of smart and original drug-like screening libraries. The company consists of 42 people (18 with Ph.D.s) and is located in its own newly built facility in the 'Parc d'Innovation d'Illkirch' near Strasbourg at the crossroads between France, Germany, and Switzerland.

ProtNeteomix (www.protneteomix.com) is a biotechnological company specialized in manufacturing miniaturized arrays (small molecules, antibodies, proteins and peptides) and array-based biomedical applications for Drug Discovery & Development. ProtNeteomix provides a top-class service tailored to the needs of biopharmaceutical industry and public laboratories.
One of the main challenges facing the pharmaceutical industry is the extremely high overall cost and time-consuming nature of Drug Discovery and Development. ProtNeteomix can provide faster and cheaper solutions based on innovative miniaturized and highly sensitive proprietary tools for obtaining valuable information about target proteins, and generating effective drugs to combat human diseases. The microarrays developed or under development can form part of various steps of DDD programs, including screening compound libraries, lead optimization and target validation, selecting the most appropriate candidates for pre-clinical trials. Our microarray-based approaches can also be used to evaluate the safety and efficacy of drug-like leads.

'Proveblue®' Pure Methylene blue!
Methylene blue is or has been used for the treatment of methemoglobinemia, urinary infections & cystitis, in endoscopic polypectomy as an adjunct to saline or epinephrine, and is used for injection into the submucosa around the polyp to be removed, as a dye in chromoendoscopy, and is sprayed onto the mucosa of the gastrointestinal tract in order to identify dysplasia, or pre-cancerous lesions, fistulae, as an ophthalmic antiseptic, for corneal staining and as a topical antiseptic and more. Methylene Blue has also been the subject of a clinical trial for Alzheimer's disease.No consistent source of supply meeting all Ph Eur specifications had been available until now. The new synthetic route is a complete in-house development and the result is Proveblue®, the Methylene blue that is essentially free of contamination. Provepharm is now preparing technical support packages for MAA, PLA, NDA, IND and IMPD
* DMF & CEP including ICH stability studies for Zones I/II/IV
* Toxicology, pharmacology data
* Clinical pharmacokinetics
* Review therapeutic, diagnostic, visualization & other clinical applications
Provepharm will supply semi-finished and finished products containing Proveblue® according to customer requirements."

PX'Therapeutics provides integrated early stage R&D, process development and cGMP manufacturing contract services for the development of biotherapeutics (recombinant proteins/monoclonal antibodies/vaccines).

Rhenovia is a biotech company managed by professionals of pharma industry and renowned neuroscientists. Our mission is to contribute to market new and more efficacious drugs to treat Alzheimer's and other diseases of the Central Nervous System (CNS) by developing new technologies that take into consideration the complexity of CNS biological systems.
Rhenovia possesses a breakthrough technology in the field of CNS with the most elaborated modelling and simulation platform applied to Drug Discovery & Development (DD&D). RHENOMS™ PFG-1 models excitatory synaptic transmission, simulates learning, memory and other brain functions.
Rhenovia provides high value added service -partnership to the pharma and biotech industry for optimization of DD&D. We are the first CNS focused company that proposes technological and conceptual solutions to:
- make DD&D: faster and cheaper,
- develop safer and more efficacious drugs
- improve success rate
by complementing the experimental approach with a validated biosimulation technology.
Rhenovia proposes to leverage on their existing drugs by searching for synergistic combinations that address the multifactorial feature of diseases, to
- expand life cycle of patent expiring blockbusters
- rehabilitate or reposition past drug candidates
- enhance late stage development candidates
by improving efficacy vs side effect, creating differentiation from competitors.

Rhône-Alpes: a dynamic biocluster initiative
· 600 companies of which 20 world leaders, positionned on 4 markets: pharmaceuticals, medical devices, biotechnologies, bioservices.
· 3 world's leading firms in human and animal vaccines, infectious disease diagnostics, and micro and nano-technologies.
· 2 worldclass competitiveness Clusters: Minalogic and Lyon Biopole respectively on nano and biotechnologies.
Rhône-Alpes biotechnologies clusters differentiate themselves form other clusters through two specific features: a transversal positioning - life sciences without barriers between the species and a marriage of the bio and IT Sector - a considerable advantage for research, clinic and industry.
· 2 research, clinical and industrial fields of expertise: infectiology and neurosciences
· 4 effective technologies-crossing projects: Canceropole Lyon-Auvergne Rhône-Alpes - CLARA, the Nanobio project, a partnership for structural biology and the Rhône-Alpes Genopole.
· 1 leading center providing 'high scale facilities' focused on biotech: Synchrotron (ESRF), neutron beam (ILL), bio-safety P4 lab, biomedical cyclotron (CERMEP), the soon-to-be Campus Charles Merieux on infectiology
International centers: International Agency for Research on Cancer (IARC), European Molecular Biology Lab (EMBL), World Health Organization...

company specialised in high added value fine chemistry, can support you in your projects of creation, implementation, optimisation and scale up of efficient ways and analysis methods

SAGI is a real-estate fund specialised in life science building in the Center of Paris.
Two clusters 'Paris Biopark' and 'Cochin' are strategic location for compagnies working in the area of human health.
Our main tenants are : Boehringer Ingelheim, Nycomede, CIRG, Inserm ...
We can also welcome you in Paris, so please contact us.

A MOLECULAR DIAGNOSTICS COMPANY, WORLDWIDE LEADER IN PERSONALIZED MEDICINE IN IMMUNOLOGY TcLand Expression is a pioneer and recognized leader in gene expression biomarkers for unmet medical needs in transplantation and auto-immune diseases. TcLand Expression Immunomonitoring Services offers through the CIMNA, a “One Stop Shop” for your Clinical Trials & Biomarker/Companion Diagnostic developments. Scientific expertise, state of the art technologies, as well as clinical monitoring, data management and statistics can be mobilized for the monitoring of the immune response and profiling of patients. TcLand Expression has developed ISO 17025 Accredited Gene Expression Central Lab Services for Biomarker/Companion Diagnostic Development & Production.

Texcell is a world-renowned CSO company that provides viral safety and immunology services in full compliance with GLP and GMP standards. Thanks to our in-depth experience of providing viral safety testing and virus validation studies, we have provided support to a large number of products now licensed by the FDA, the EMEA and the MHW. Texcell is also your central lab for pre-clinical and clinical trials. We offer a dedicated technology platform in immunology. Based in France (Evry), we created last July a subsidiary in USA with a Manager based in Boston, MA.

Transgene is a biopharmaceutical company based in Strasbourg, France, that designs and develops therapeutic vaccines and immunotherapy products for the treatment of cancers and infectious diseases. Its expertise covers all product development stages, including research, production of clinical batches and conducting clinical trials. Four products are currently in clinical development, three of which are at the phase II trial stage. A partnership agreement has been signed with Roche for subsequent development of one of these products. Transgene has a number of exclusive and innovative technologies using viral vectors. Transgene is listed on the Paris stock exchange (NYSE - Euronext Compartment B).

Trophos is a clinical stage company focused on neurology & cardiology with a novel portfolio of mitochondrial pore modulator drug candidate, with a lead product in Phase 2.

New approach in immunosuppressive strategies

Txcell strategy is to develop investigational products in a new class of autologous cellular immunotherapies that are uniquely designed to regulate the patient's own immune system.

Autologous cellular immunotherapies hold promise because they may provide patients meaningful clinical benefits with low toxicity.

TxCell develops innovative treatments for Crohn's (phase I/IIa) and Rheumatoid Arthritis patients (pre-clinical stage).

TxCell is a spin-off from the French Medical Research Institute (INSERM) . Contact David Dellamonica Director Business Development.
Les Cardoulines, Allée de la nertière
06560 Valbonne, Sophia Antipolis FRANCE
dellamonica@txcell.com www.txcell.com

Universal Biotech is a subsidiary of Universal Medica Group providing consulting services to biotechnology innovation market players and brings to its customers efficiency and know-how in strategy, financing, management and marketing of innovation.

VALYSCO is a Company dedicated to the development of Life Sciences through the counselling of private and public stake holders in human, animal, plant health and nutrition. Today, in the Life Sciences world, globalisation and multiple scientific breakthroughs generate the need for both broad multidisciplinary vision and in depth expertise. VALYSCO contributes to a more efficient global & transversal development of your projects through the commitment of its senior professionals in an international environment. VALYSCO masters the Life Sciences value chain from research to market, from prevention (nutrition, diagnostics, vaccines ...) to treatment (pharmaceuticals, diagnostics ...) and well being monitoring.

VIVALIS (NYSE- Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops for the treatment of viral diseases.

VOXCAN provides pre-formatted or made-to-order medical imaging services for pre-clinical or research studies in fields such as bone and cartilage, cardio-vascular, oncology and some metabolic and pulmonary diseases.

Watchfrog's Technology reveals the potential of new molecules by rapid in vivo testing using specifically designed amphibian models. This test methodology combines the biological pertinence of in vivo analysis with the flexibility of in vitro tools. Watchfrog's adaptive technology delivers cost-effective predictability tests for human healthcare. The newest tests are allied to the development of amphibian models that 'light up' (emission of fluorescence) when a biological function is activated.

Zeta Biotech has designed and markets a new technology of conservation for bio molecules and applies it on Polyacrylamide Gels today
The Company supplies the lowest operational expenditure (OpEx) and smartest electrophoresis gels
Among several advantages, we can highlight the following ones :
UltraPag are dehydrated vertical gel electrophoresis.
They showed enhanced performances with a better resolution and a shortest migration time (reduced by 50 %).
UltraPag gels can be stored for up to 24 months at room temperature allowing shipping without dry ice,carboglace, and storage requiring no fridge or cold room.
Easy to use and toxic-free.
UltraPag gels are provided with a reusable universal cassette enabling them to be used in the main SDS-PAGE systems.
Zetabiotech was incorporated in October 2005 by Antony Guyader, a post-graduate in chemistry and Bruno Viola, having a Masters degree in Business Administration
The firm is quoted on the stock market Nyse Euronext Paris FR0010485516- MLZTA.
Zeta Biotech has developed and patented a new generation of electrophoresis Media